Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Treatment Resistant Depression
NCT04021433Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Sep 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by Hadassah Medical Organization. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 1 month. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04021433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021433.